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Abstract Scavenger eceptors bind modified low-density lipo- 
proteins (LDL) on a collagen-like domain which possesses a
lysine cluster at the carboxy end. We previously constructed a 
receptor model peptide containing the lysine cluster. In the 
present study, we evaluated the ligand specificity of the receptor 
model peptide. It selectively bound modified-LDLs, and not 
LDL. The binding of acetylated-LDL (Ac-LDL) was inhibited 
by dextran sulfate, fucoidan, and sulfatides in a manner similar 
to that of the natural receptor. Both polyguanylic and 
polyinosinic acids inhibit the Ac-LDL binding whereas poly- 
cytidylic acid did not. These results indicate that the lysine 
cluster in the collagen-like domain has important roles in both 
ligand binding and ligand specificity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The scavenger receptor has broad binding specificity and 
recognizes a variety of macromolecules. It binds modified 
low-density lipoproteins (LDL) and internalizes them into 
the cell. The excessive uptake of modified LDL causes the 
conversion of macrophages into foam cells [1 5]. These cells 
contain excess cholesterol esters and form fatty streaks and 
atherosclerotic lesions. The receptor also binds ]3-amyloid 
peptides and may cause the onset of Alzheimer's disease [6]. 
Moreover, it binds advanced glycation end products (AGE), 
and AGE binding may be involved in the aging process and in 
diabetic omplications [7]. Thus the scavenger receptor partic- 
ipates in the onset of several diseases. Furthermore, the re- 
ceptor binds fucoidan, sulfatides, dextran sulfate, maleylated 
BSA, polyinosinic acid (poly I), and polyguanylic acid (poly 
G) [8]. On the other hand, it does not bind LDL, BSA, poly- 
cytidylic acid (poly C), and polyadenylic acid (poly A). In this 
way, the receptor has broad ligand-binding specificity but re- 
tains the ability to distinguish certain macromolecules. 
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LPDS, lipoprotein-deficient serum; EDTA, ethylenediaminetetraacetic 
acid; HEPES, 4-(2-hydroxyethyl)-l-piperazineethane-sulfonic acid; 
h, 4-hydroxyproline; Ahx, aminohexanoic a id; 13Ala, [3-alanine 
The type I bovine macrophage scavenger receptor consists 
of 453 amino acids, as deduced from its nucleotide sequences 
[9 13], and exists in a trimerized form. It is divided into six 
domains: an N-terminal cytoplasmic (50 a.a.), a membrane- 
spanning (26 a.a.), a spacer (32 a.a.), an c~-helical coiled-coil 
(163 a.a.), a collagen-like (72 a.a.), and a C-terminal type- 
specific (110 a.a.) domains. Analyses of deletion mutants 
from the C-terminus of the type I receptor showed that the 
collagen-like domain was essential for ligand binding and that 
the e~-helical coiled-coil domain was important for maintain- 
ing a trimeric structure. Analyses of point mutants in the 
collagen-like domain indicated that four Lys residues, at 
327, 334, 337, and 340, which form a lysine cluster, were 
necessary for ligand binding [14]. We constructed a receptor 
model peptide derived from Gly 323 to Lys 34°, including the 
lysine cluster of the bovine scavenger receptor, and showed 
that it formed a collagen structure and bound Ac-LDL 
[15,161. 
In this study, in order to further evaluate the role of the 
lysine cluster, we analyzed the ligand binding specificity of the 
receptor model peptide and compared it with that of the nat- 
ural scavenger receptor. Here we show that the receptor mod- 
el peptide has ligand binding specificity similar to that of the 
natural scavenger receptor, indicating that the lysine cluster is 
involved in not only ligand binding but also in ligand specif- 
icity. 
2. Materials and methods 
2.1. Materials" 
Dulbecco's modified Eagle medium (DMEM) and fetal calf serum 
(FCS) were purchased from Gibco (Grand Island, NY). Na125I was 
purchased from DuPont New England Nuclear (Boston, MA). Strep- 
tavidin-Dynabeads M-280 were purchased from DYNAL A.S. (Oslo, 
Norway). Female ddY mice were obtained from Nihon SLC Co. 
(Shizuoka, Japan). All other reagents were purchased from Sigma 
(St. Louis, MO). 
2.2. Receptor model peptide and (GPK)6 peptide 
The triple stranded receptor model peptide was prepared as de- 
scribed previously [15,16]. The triple stranded (Gly Pro-Lys)~;, 
(GPK)6 peptide, was prepared by the same method. 
Streptavidin-Dynabeads M-280 (0.5 ml) were washed with 5 mM 
phosphate buffer (pH 7.4) containing 150 mM NaC1. The beads were 
then mixed with the biotinylated peptide (2.5 nmol) dissolved in the 
same buffer. After 30 min at room temperature, the peptide resin was 
washed 3 times with the same buffer, and was suspended in 0.5 ml of 
the same buffer. About 100 pmol of peptide were coupled to the beads 
(100 ~tl). Prior to the binding assay, the peptide resin (0.5 ml) was 
resuspended in 0.25 ml of DMEM. 
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2.3. Lipoproteins 
LDL was isolated from normolipidemic human plasma, containing 
0.1% EDTA, 0.02% sodium azide, and 0.5 mg/ml benzamidine, at a 
density of 1.019 1.063 g/ml by sequential ultracentrifugation [17]. The 
lipoprotein-deficient serum (LPDS) was also isolated at a density 
greater than 1.21. LDL was acetylated by repeated additions of acetic 
anhydride as described [18], or was oxidized by exposure to CuSO4 as 
described [19]. Ac-LDL was radioiodinated at a specific activity of 
100 300 cpm/ng protein with Nar-'r'l, using the iodine monochloride 
method [20]. 
2.4. Macrophagcs 
Mouse peritoneal macrophages were prepared according to the 
method of Cohn and Morse [21]. Peritoneal macrophages were har- 
vested in phosphate-buffered saline without Ca 2~ and Mg 2+ (PBS[-]) 
from non-stimulated female ddY mice (25 30 g). The cells were cen- 
tritilged at 800×g for 5 min, washed once with PBS[ ], and sus- 
pended at 2x 10 ~; cells/ml in DMEM containing 10% FCS, 100 U/ 
ml penicillin, and 100 lag/ml streptomycin. The cell (1 ml) suspension 
was plated in 12-well plastic dishes. After an incubation at 37°C for 
2 h, the non-adherent cells were removed by washing twice with 
DMEM. Adherent cell monolayers were cultured with 1 ml of 
DMEM containing 10% FCS, and were used for the binding assay 
on the next day. 
2.5. Ac-LDL binding assay 
The peptide resin suspension (8 ~tl in DMEM) was mixed with 15 
p_g/ml J2aI-Ac-LDL and a drug in DMEM containing 10 mM HEPES- 
Na (pH 7.4) and 10% LPDS, in a total volume of 50 ~tl, and was 
incubated for 2 h at 4°C. Non-specific binding was estimated by using 
beads lacking the biotinylated peptide. After the incubation, the pep- 
tide resin was washed 3 times with ice-cold 50 mM Tris-HC1 (pH 7.4), 
150 mM NaCI, and 2 mg/ml BSA. Bound 12'~I-Ac-LDL was eluted 
with 50 mM NaC1, 10 mM HEPES-Na (pH 7.4), and 4 mg/ml dextran 
sulfate for 1.5 h at 4°C, and the radioactivity of the eluted IeqI-Ac- 
LDL was counted in a gamma counter. 
The cells were pre-incubated in DMEM containing l0 mM HEPES- 
Na (pH 7.4) and 10% LPDS for 30 rain at 4°C. The medium was then 
changed to 1 ml of DMEM containing 10 mM HEPES-Na (pH 7.4), 
10% LPDS, 10 btg/ml L2:'I-Ac-LDL, and a drug, and the cells were 
further incubated for 2 h at 4°C. Non-specific binding was estimated 
in the presence of a 40-fold excess of unlabeled Ac-LDL. After the 
incubation, the cells were washed once rapidly and twice for 10 min 
with ice-cold 50 mM Tris-HC1 (pH 7.4), 150 mM NaC1, and 2 mg/ml 
BSA, and were washed once with ice-cold 50 mM Tris-HC1 (pH 7.4), 
and 150 mM NaCI. Bound ~251-Ac-LDL was eluted with 50 mM 
NaCI, 10 mM HEPES-Na (pH 7.4), and 4 mg/ml dextran sulfatc 
for 1.5 h at 4°C, and the radioactivity of the eluted 12~I-Ac-LDL 
was counted in a gamma counter. The amount of the released ~er'I- 
Ac-LDL by dextran sulfate represents the amount of the surface- 
bound I~r'I-Ac-LDL. After the elution of the bound 12~I-Ac-LDL, 
the cells were dissolved in 0.l N NaOH, and the protein concentration 
of the cell lysate was determined by the method of Lowry et al. [22]. 
Receptor model peptide 
~, -  (G Ph)4-GKTG KPGLNGQKGQKGEK-(GPh ) 3 
L~GPh)4-G KTG KPGLNGQKGQKGEK-tGPh) 3 
(GPh)4-GKTGKPGLNGQKGQKGEK-(GPh) 3 
(GPK) 6 peptide 
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Fig. t. Structures of the receptor model peptide, the (GPK)~ pep- 
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Fig. 2. Activities of 12:'I-Ac-LDL binding to the receptor model pep- 
tide (O) and the (GPK)~; peptide (O). The resin, immobilized with 
either the receptor model peptide or the (GPK)~i peptide, was incu- 
bated with various amounts of ler'I-Ac-LDL at 4°C for 2 h. The 
amount of ~2aI-Ac-LDL bound to the peptides was measured as de- 
scribed in Section 2. Each point represents the mean of duplicate 
determinations. 
3. Results 
3.1. Ac-LDL binding to the receptor model peptide 
Fig. 1 shows the structures of receptor model peptide mim- 
icking the lysine cluster in the collagen-like domain of the 
bovine macrophage scavenger receptor. The three collagenous 
peptides, in which a peptide encompassing residues 323 to 340 
of the bovine macrophage scavenger eceptor is surrounded 
by four and three repeats of a Gly Pro Hyp triad, are cross- 
linked at their amino termini. Both the cross-linking and the 
addition of the G ly -Pro -Hyp triad facilitate the formation of 
a collagen structure and increase the stability. Biotin was at- 
tached to the anchor molecule of the three collagenous pep- 
tides to immobilize the receptor model peptide to the support. 
Since the Lys residues are involved in ligand binding, a tris-N- 
terminal cross-linked (Gly-Pro Lys)t~, (GPK)6 peptide, was 
also prepared as a control peptide. The Lys residues appear 
at every Y position of the Gly X Y sequence, which is char- 
acteristic of a collagenous equence. This peptide also exhib- 
ited a collagen structure from the CD spectrum, with a mid- 
point of thermal transit ion (T,,) of 42°C (data not shown). 
In order to analyze the Ac-LDL binding, the two peptides 
immobilized on the Dynabeads were incubated with 5 25 lag/ 
ml of I~r'I-Ac-LDL for 2 h at 4°C. The radioactivity of the 
te:' l-Ac-LDL bound to the peptides was measured. Binding of 
Ac-LDL to both the receptor model peptide and the (GPK)~ 
peptide was dose dependent (Fig. 2). The amount of Ac-LDL 
bound to the (GPK)6 peptide was 4 times greater than that 
bound to the receptor model peptide. Scatchard analyses how 
apparent dissociation constants (Kd) of 31 lag/ml for the re- 
ceptor model peptide and 6.8 btg/ml for the (GPK)t~ peptide, 
respectively. With the same experiment, the mouse peritoneal 
macrophages has an apparent K,i of 3.2 p.g/ml {data not 
shown). Therefore the binding activitiy of the receptor model 
peptide is 10-fold lower than that of the macrophages. We 
used a concentrat ion of 15 gg/ml of v-'aI-AcLDL in the fol- 
lowing experiments. 
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Fig. 3. Competition of 12SI-Ac-LDL binding to the receptor model 
peptide by LDL, Ac-LDL, and Ox-LDL. The resin immobilized 
with the receptor model peptide was incubated with 15 /.tg/ml of 
125I-Ac-LDL at 4°C for 2 h. The unlabeled LDL (O), Ac-LDL (•) ,  
and Ox-LDL (11) were added at the indicated concentrations. The 
amount of 125I-Ac-LDL bound to the peptide was measured as de- 
scribed in Section 2. In the absence of the competitors, the amount 
of ~25I-Ac-LDL bound was 30 ng/tube. Each point represents the 
mean of two experiments. 
3.2. Binding of  LDL, Ac-LDL, and Ox-LDL 
The scavenger receptor binds modified-LDLs, such as Ac- 
LDL and Ox-LDL, and not LDL [12]. A competitive inhib- 
ition assay was performed to examine the effects of modified 
lipoproteins on 125I-Ac-LDL binding to the receptor model 
peptide. Binding of 125I-Ac-LDL to the receptor model pep- 
tide was inhibited competitively by the addition of an excess 
of unlabeled Ac-LDL or Ox-LDL (Fig. 3). The inhibitory 
activity of Ac-LDL was higher than that of Ox-LDL. The 
addition of 600 gg/ml Ac-LDL reduced the bound 1251- 
AcLDL to 7.7% of the control, while the addition of 600 
gg/ml Ox-LDL reduced it to 20.8%. On the other hand, the 
addition of excess of unlabeled LDL at the concentration of 
600 gg/ml had no effect. Thus, the receptor model peptide 
binds modified-LDLs, and not LDL. 
3.3. Binding specificity 
Many compounds are known to inhibit Ac-LDL binding to 
the natural scavenger receptor [8]. To analyze the binding 
specificity of the receptor model peptide, we tested fucoidan, 
sulfatides, dextran sulfate, poly I, and poly G as inhibitor 
molecules, and poly C as a control molecule. The inhibition 
mode of the receptor model peptide was compared to those of 
the scavenger receptor of mouse peritoneal macrophages and 
the (GPK)6 peptide. The macrophages have several receptors 
to bind modified-LDLs; however, 70% of Ac-LDL binding is 
mediated by the scavenger eceptor (types I and II) [23]. 
Therefore, we consider here that the Ac-LDL binding by 
the macrophages is mediated by the scavenger receptor. 
Fig. 4 shows the percent inhibition of 12SI-Ac-LDL binding 
by the compounds described above. Dextran sulfate, fucoidan, 
and sulfatides inhibited Ac-LDL binding to the natural recep- 
tor expressed on mouse peritoneal macrophages in a dose- 
dependent manner (Fig. 4A). Dextran sulfate showed the 
strongest inhibition of Ac-LDL binding (IC50, 0.15 ~tg/ml), 
while the inhibition by fucoidan was a little weaker (IC50, 
0.35 ~tg/ml). Sulfatides inhibited Ac-LDL binding with the 
IC50 value of 3.5 lag/ml, although the inhibition was 10-20 
times weaker than those of dextran sulfate and fucoidan. Sim- 
ilar inhibition tendencies by dextran sulfate, fucoidan, and 
sulfatides were observed with the receptor model peptide 
(IC50, 0.7, 0.5 and 8 ~tg/ml, respectively), although the inhib- 
itions were 2-fold weaker (Fig. 4B). Sulfatides howed more 
than 10-fold weaker inhibitory activity with both receptors 
than dextran sulfate and fucoidan. Thus, the receptor model 
peptide has a similar ligand binding specificity to the natural 
receptor. On the other hand, when the (GPK)6 peptide was 
used, dextran sulfate, fucoidan and sulfatides howed almost 
same inhibition (ICs0, 2.5-7 ~tg/ml) (Fig. 4C), indicating the 
absence of ligand binding specificity by the (GPK)6 peptide. 
Poly G and poly I are known to be effective inhibitors of 
Ac-LDL binding to the scavenger receptor, but poly C is in- 
effective. We obtained the same results using the natural re- 
ceptor, as shown in Fig. 5A. The IC50 values of both poly G 
and poly I were 0.15 ~tg/ml. Poly C did not show any inhib- 
itory activity. When the receptor model peptide was tested, 
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Fig. 4. Inhibition of 125I-Ac-LDL binding to the natural receptor of mouse peritoneal macrophages (A), the receptor model peptide (B), and 
the (GPK)6 peptide (C), by fucoidan, sulfatides, and dextran sulfate. Mouse peritoneal macrophages were incubated with 10 ~tg/ml of 12SI-Ac- 
LDL at 4°C for 2 h. The resin, immobilized with either the receptor model peptide or the (GPK)6 peptide, was incubated with 15 I.tg/ml of 
12SI-Ac-LDL at 4°C for 2 h. Fucoidan (O), sulfatides (•),  and dextran sulfate (11) were added at the indicated concentrations. The amount of 
12SI-Ac-LDL bound to the macrophages or the peptides was measured as described in Section 2. In the absence of the inhibitors, the amounts 
of x2SI-Ac-LDL bound were 192 ng/mg cell protein (A), 51 ng/tube (B), and 430 ng/tube (C), respectively. Each point represents he mean of 
duplicate determinations (A) or two experiments (B), (C). 




























1 10 t00 
Concentration (~tg/ml) 
Fig. 5. Inhibition of 12:'I-Ac-LDL binding to the natural receptor of mouse peritoneal macrophages (A), the receptor model peptide (B), and 
the (GPK)6 peptide (C) by poly l, poly G, and poly C. Mouse peritoneal macrophages were incubated with 10 gg/ml of ~2r'I-Ac-LDL at 4°C 
for 2 h. The resin, immobilized with either the receptor model peptide or the (GPK)6 peptide, was incubated with 15 gg/ml of ~25I-Ac-LDL at 
4°C for 2 h. Poly I (O), poly G (zx), and poly C (D) were added at the indicated concentrations. The amount of l~rq-Ac-LDL bound to macro- 
phages or the peptides was measured as described in Section 2. In the absence of the inhibitors, the amounls of ~25I-Ac-LDL bound were 192 
ng/mg cell protein (A), 51 ng/tube (B), and 430 ng/tube (C), respectively. Each point represents he mean of duplicate determinations (A) or 
two experiments (B), (C). 
the inhibitory activities of poly G and poly I were 20- and 40- 
fold reduced with the ICr,~ values of 2 and 7 ~tg/ml, respec- 
tively (Fig. 5B). Inhibition by poly C was also observed, but 
to a much lower extent. This shows that the receptor model 
peptide still has binding specificity, although it was reduced. 
On the other hand, the (GPK)(~ peptide did not discriminate 
between poly G, poly I, and poly C (Fig. 5C). They showed 
the same inhibitory activities with ICs0 values of 8-30 lag/ml. 
In comparison with the receptor model peptide, the inhibitory 
activities of poly G and poly I were 3-fold lower, while that of 
poly C was greatly enhanced. As a consequence, poly G, poly 
I, and poly C showed the same levels of inhibition. 
4. Discussion 
In the present study, we analyzed the ligand binding specif- 
icity of the receptor model peptide from Gly 323 to Lys 34°, 
including the lysine cluster, of the bovine scavenger receptor. 
The receptor model peptide specifically bound modified- 
LDLs, and this binding was inhibited by Ac-LDL and Ox- 
LDL. On the other hand, LDL did not have any inhibitory 
activity, even with an excess of ligand (Fig. 3). These charac- 
teristics coincide with those of the natural receptor [12]. Com- 
paring the binding of Ac-LDL and Ox-LDL, Ac-LDL binds 
more strongly than Ox-LDL, implying that the binding sites 
for Ac-LDL and Ox-LDL might be somewhat different. The 
binding characteristics of Ac-LDL and Ox-LDL to the natu- 
ral receptor are also different, since the substitutions of the 
Lys residues with Ala residues in the lysine cluster educed the 
Ac-LDL binding more than the Ox-LDL binding [14]. This 
suggests that the binding site for Ox-LDL may shift toward 
the middle of the collagen-like domain. The receptor model 
peptide is derived from the lysine cluster of the collagen-like 
domain, and therefore the binding of Ox-LDL to the receptor 
model peptide was weaker than that of Ac-LDL. 
Inhibition of Ac-LDL binding to the receptor model pep- 
tide by dextran sulfate, fucoidan, and sulfatides howed ten- 
dencies similar to those of the natural receptor, althought 2- 
fold higher amounts of inhibitors were needed for 50% inhib- 
itions (Fig. 4A,B). This indicates that the affinities of the in- 
hibitors to the receptor model peptide were twice as affected 
as that of Ac-LDL. The inhibitions by poly G and poly 1 were 
20~0-fold weaker, whereas the inhibition by poly C was de- 
tectable, but slight (Fig. 5A,B). Thus, the receptor model pep- 
tide has ligand specificity, although the ligand discrimination 
is weaker than that of the natural receptor. 
The (GPK)6 peptide showed 4-fold higher affinity for Ac- 
LDL than the receptor model peptide (Fig. 2). The binding 
affinity may be influenced by the number of kys residues. For 
example, the (GPK)6 peptide has six Lys residues, while the 
receptor model peptide has five. The increasing number of 
positive charges enhances the binding of Ac-LDL. However, 
the (GPK)6 peptide did not possess ligand binding specificity 
(Fig. 4CFig. 5C). This indicates that other amino acids, in 
addition to the Lys residues, participate in the ligand binding 
specificity. In the bovine scavenger receptor, three Lys resi- 
dues are at the Y positions and two Lys residues are at the X 
positions of the Gly X Y sequences, with a three amino acid 
interval in the lysine cluster of the collagen-like domain 
[10,11]. The positions of the Lys residues might be important 
for ligand binding specificity. The amino acid sequences with- 
in the lysine cluster are well conserved among the bovine, 
human, mouse, and rabbit scavenger receptors [10,11,14,24]. 
These results further suggest hat the receptor model pep- 
tide has a similar binding specificity to that of the natural 
scavenger receptor, and that the target site for Ac-LDL is 
the lysine cluster. Therefore, the receptor model peptide 
should be a valuable tool to study the strncture function re- 
lationship and the ligand binding specificity of the scavenger 
receptor. The scavenger receptor may be a possible target for 
the development of drugs for atherosclerosis, Alzheimer's dis- 
ease, and diabetic complications. For example, blocking the 
excessive uptake of modified lipoproteins through the macro- 
phage scavenger receptor is expected to suppress foam cell 
formation, and treatments using scavenger receptor inhibitors 
may be able to prevent atherosclerosis. One of the appli- 
cations of this receptor model peptide will be to establish a 
cell-free assay system to search for scavenger receptor inhib- 
itors, as well as a means to perform high-through-put screen- 
ing. 
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